Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Indoco Remedies gains 7% after zero observation from USFDA

The inspection was held from October 14 to 18.

October 18, 2019 / 03:38 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Indoco Remedies added more than 7 percent intraday on October 18 after USFDA completed inspection with zero 483s.

The company's clinical research organisation (CRO), AnaCipher, located at Hyderabad successfully cleared the United States Food and Drug Administration (USFDA) inspection with zero 483s, as per the company release.

The inspection was held from October 14 to 18.

"This achievement is for the fifth time in a row and confirms the capabilities of our team at the CRO for maintaining highest quality standards and excellence in servicing our clients," said Aditi Kare Panandikar, Managing Director, Indoco Remedies.

The CRO - AnaCipher conducts Bio-Equivalence and Bio-Availability (BA/BE) studies at its facility in Hyderabad and is spread over an area of 30,000 sq. ft. with 98 beds.

At 15:25 hrs, Indoco Remedies was quoting at Rs 151.65, up Rs 7.30, or 5.06 percent, on the BSE.

Moneycontrol News
first published: Oct 18, 2019 03:38 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347